Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Yuna Youn

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1026-6748; OpenAlex author ID A5056310026. Sources: OpenAlex.

Their work

Papers
12 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2019: 1 paper · 2020: 3 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 3 papers · 2026: 3 papers

Papers 12

  1. Comprehensive clinico-genomic analysis of pancreatic ductal adenocarcinoma: Overcoming biases and limitations. Co-author DOI 10.1016/j.canlet.2025.218176↗
  2. Sensitive fiber-optic localized surface plasmon resonance sensor for early pancreatic cancer detection via carbohydrate antigen 19-9 and supplementary biomarke… Co-author DOI 10.1016/j.talanta.2025.129133↗
  3. Early diagnosis of pancreatic ductal adenocarcinoma by signal-enhanced lateral flow immunoassay: SELFI. Co-author DOI 10.1038/s41467-026-69204-7↗
  4. Development of a serum protein biomarker panel for the diagnosis of pancreatic ductal adenocarcinoma using a machine learning approach. Co-author DOI 10.1038/s41598-025-19631-1↗
  5. Novel mRNA biomarker-based liquid biopsy for the detection of resectable pancreatic cancer. Co-author DOI 10.1186/s12885-025-14124-w↗
  6. Quantitative immunohistochemistry analysis of pancreatic adenocarcinoma upregulated factor expression in pancreatic cancer and its prognostic significance. Co-author DOI 10.4251/wjgo.v17.i9.109055↗
  7. Novel mRNA-based Immunological Biomarker for Early Detection of Resectable Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-2658368/v1↗
  8. Downregulation of ASF1B inhibits tumor progression and enhances efficacy of cisplatin in pancreatic cancer. First author DOI 10.3233/cbm-210490↗
  9. Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 tria… Co-author DOI 10.1016/j.gie.2020.02.012↗
  10. Cdc6 disruption leads to centrosome abnormalities and chromosome instability in pancreatic cancer cells. Co-author DOI 10.1038/s41598-020-73474-6↗
  11. Involvement of the NF-κB signaling pathway in proliferation and invasion inhibited by Zwint-1 deficiency in Pancreatic Cancer Cells. First author DOI 10.7150/jca.46173↗
  12. Non-SMC condensin I complex subunit H mediates mature chromosome condensation and DNA damage in pancreatic cancer cells. First author DOI 10.1038/s41598-019-54478-3↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin‐Hyeok Hwang · 11 shared papers, 2019–2026 · strength 2.31
  2. Jong-Chan Lee · 8 shared papers, 2020–2026 · strength 1.68
  3. Jaihwan Kim · 7 shared papers, 2020–2026 · strength 1.30
  4. Jae Hyeong Kim · 7 shared papers, 2019–2026 · strength 1.29
  5. Kwangrok Jung · 3 shared papers, 2025–2026 · strength 0.78
  6. Dong Woo Shin · 2 shared papers, 2020–2025 · strength 0.45
  7. Hyeong‐Min Kim · 1 shared paper, 2026 · strength 0.29
  8. Seung-Ki Lee · 1 shared paper, 2026 · strength 0.29
  9. Sohyeon Jang · 1 shared paper, 2026 · strength 0.24
  10. Bong‐Hyun Jun · 1 shared paper, 2026 · strength 0.24
  11. Ji Kon Ryu · 1 shared paper, 2022 · strength 0.19
  12. Jong-chan Lee · 1 shared paper, 2020 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.